Mumps Vaccine (MumpsVax) Market Report 2026

Mumps Vaccine (MumpsVax) Market Overview

• The Mumps Vaccine (MumpsVax) market growth in the historic period has been driven by high incidence of mumps outbreaks, introduction of routine childhood immunization • Market expansion is supported by need to prevent re-emerging outbreaks, strengthening of school immunization policies • Growth Driver: Mumps Resurgence Highlights Need For Boosters Amid Waning Vaccine Protection • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Mumps Vaccine (MumpsVax) Market?

Mumps vaccine (MumpsVax) is a live attenuated vaccine that prevents mumps using the Jeryl Lynn strain of the virus. Administered in two doses, it is often combined with the MMR (measles, mumps, rubella) vaccine and provides over 95% protection against mumps. Although standalone production has ceased, mumps vaccine (mumpsvax) remains crucial for public health efforts to reduce mumps outbreaks and has significantly lowered incidence rates in vaccinated populations. The main product types of mumps vaccine (mumpsvax) are monovalent, combinational, divalent, trivalent, and others. Monovalent vaccines target only mumps, while combinational vaccines protect against multiple diseases, such as measles and rubella, in one shot. The age group includes pediatrics and adults, and distribution channels are hospital pharmacies, drug stores, and retail pharmacies. It is used by various end-users such as pediatric clinics, hospitals, non-governmental organizations (NGOs), and other end-users.

What Is The Mumps Vaccine (MumpsVax) Market Growth Forecast?

The growth in the forecast period can be attributed to need to prevent re-emerging outbreaks, strengthening of school immunization policies, expansion of global vaccination coverage, focus on herd immunity maintenance, public health surveillance improvements. Major trends in the forecast period include sustained demand for combination vaccines, focus on pediatric immunization programs, continued use in outbreak control strategies, integration with national immunization schedules, emphasis on long-term population immunity.

Global Mumps Vaccine (MumpsVax) Market Segmentation

1) By Product Type: Monovalent, Combinational, Divalent, Trivalent, Other Product Types 2) By Age Group: Pediatric, Adult 3) By Distribution Channels: Hospital pharmacies, Drug Stores, Retail Pharmacies 4) By End-User: Pediatric Clinic, Hospitals, Non-Governmental Organization (NGOs), Other End-Users

What Are The Drivers Of The Mumps Vaccine (MumpsVax) Market?

Rising prevalence of infectious diseases is expected to propel the growth of the mumps vaccine (mumpsvax) market going forward. Infectious diseases are illnesses caused by pathogenic microorganisms, such as viruses, bacteria, fungi, or parasites, that can be transmitted from one individual to another or through contaminated environments. The increase in the prevalence of infectious diseases is primarily driven by factors such as urbanization, climate change, globalization, and changes in human demographics and behavior, which enhance the transmission and emergence of pathogens. Mumpsvax, a mumps vaccine, is primarily used to prevent mumps infection, which is an infectious disease caused by the mumps virus, often included in the MMR (measles, mumps, rubella) vaccination. For instance, in August 2024, according to a report published by the UK Health Security Agency, a UK-based government agency, in 2023, the West Midlands region reported the highest number of measles cases, with 160 cases (44%), followed by London with 122 cases (33%). Notably, children under the age of 10 represented 63% of the total cases, amounting to 232 cases. Measles activity saw a significant rise towards the end of the year, with 157 new cases recorded in December, compared to just 45 cases in November. Therefore, the rise in the prevalence of infectious diseases is driving the mumps vaccine (mumpsvax) industry. Rising healthcare expenditure is expected to propel the growth of the mumps vaccine (mumpsvax) market going forward. Healthcare expenditure refers to the total amount spent on health care goods and services, including personal health care, preventive services, and public health activities, aimed at improving health outcomes within a specific period. The rising healthcare expenditure is due to an aging population, chronic diseases, advanced medical technology, high drug prices, inefficient payment models, and increased demand for services. Rising healthcare expenditure affects mumps vaccine (mumpsvax) by boosting funding for vaccination initiatives, which can improve access to the vaccine and lead to better public health outcomes through increased immunization rates against mumps. For instance, in May 2024, according to a report published by Office for National Statistics, a UK-based government agency, total healthcare expenditure rose by 5.6% in nominal terms from 2022 to 2023, compared to a growth rate of 0.9% in 2022. Additionally, total long-term health and social care expenditure increased by 2.8% in real terms in 2022. Therefore, the rising healthcare expenditure is driving the mumps vaccine (mumpsvax) industry. The increasing number of clinical trials is expected to propel the growth of the mumps vaccine (mumpsvax) market going forward. Clinical trials play a crucial role in advancing the understanding and treatment of Acute Spinal Cord Injury (SCI). Mumpsvax provides targeted immunity against the mumps virus that helps clinical trials by serving as a reliable tool for evaluating vaccine efficacy, safety, and immune response, particularly in studies focused on viral infections and pediatric immunization strategies. For instance, in December 2024, according to the Association of the British Pharmaceutical Industry (ABPI), a UK-based organization, reported that the total number of clinical trials initiated in the UK rose from 411 in 2022 to 426 in 2023. Therefore, the increasing number of clinical trials drives the mumps vaccine (mumpsvax) industry.

Key Players In The Global Mumps Vaccine (MumpsVax) Market

Major companies operating in the mumps vaccine (mumpsvax) market are Merck & Co. Inc., GlaxoSmithKline plc

Regional Insights

North America was the largest region in the mumps vaccine (mumpsvax) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Mumps Vaccine (MumpsVax) Market?

The mumps vaccine (mumpsvax) market consists of sales of mumps vaccines, including both standalone mumps vaccines and combination vaccines. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Mumps Vaccine (MumpsVax) Market Report 2026?

The mumps vaccine (mumpsvax) market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the mumps vaccine (mumpsvax) industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.